New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
09:29 EDTRPRXRepros updates Adroxal study, requests end of Proellex Phase 2 study
Repros Therapeutics provided an update for both of its core clinical programs. As part of the FDA requirement for total number of subjects to be exposed for six months, the company is conducting a 500 subject open label study. To date, the company has enrolled 499 subjects and expects the study to be fully enrolled this week. The company has sent a "request for guidance" letter to the FDA. The key points were the identification of a single high enrolling site with a population whose baseline characteristics appear different from the other sites; the company has proposed enrolling an additional 40 subjects into each of the two pivotal studies to allow for subset analysis while retaining the power of the original protocols; the company proposed moving two sites from the enrolling study ZA-302 to the closed for enrollment study ZA-301. When the company receives guidance from FDA, it will update the financial community. The company has requested an end of Phase 2 meeting for its vaginal Proellex program for the treatment of uterine fibroids. The request was for a meeting before the end of April.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
12:46 EDTRPRXRepros Therapeutics volatility at low end of six-month range
Repros Therapeutics overall option implied volatility of 102 compares to its 26-week average of 111 according to Track Data, suggesting decreasing price movement.
November 13, 2014
10:44 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 12, 2014
10:34 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI RPRX KATE PNK CZR KING TSLA UBNT LOCO GNRC
November 11, 2014
10:39 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
November 10, 2014
10:17 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: RMTI ACHN RPRX ARCP SALE ZU KING UBNT KATE AWAY
09:04 EDTRPRXRepros Therapeutics reports Q3 EPS 32c, consensus (39c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use